{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:13:23Z","timestamp":1777929203993,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>As there is a lack of reports on the association between anti-lipoprotein lipase (anti-LPL) antibodies and dyslipoproteinemia, we aimed to analyse the association between anti-LPL antibodies and the clinical and serological characteristics of patients with systemic lupus erythematosus (SLE) and cardiovascular (CV) events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty patients with SLE were examined for the presence of anti-LPL antibodies via western blotting. Data on laboratory findings and the occurrence of CV events were retrospectively collected and evaluated. Patients with SLE were classified into two groups according to the detection of anti-LPL antibodies: anti-LPL antibody-positive and antibody-negative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Anti-LPL antibody immunoglobulin G was detected in 28 patients with SLE (35.0%). Additionally, triglyceride levels tended to be higher in the anti-LPL antibody-positive group than in the anti-LPL antibody-negative group. The former exhibited significantly higher levels of serum albumin, anti-Smith antibody, and IgM than the latter. The incidence of CV events was higher in the anti-LPL antibody-positive group than in the anti-LPL antibody-negative group (35.7% vs 5.8%,\n                      <jats:italic>p<\/jats:italic>\n                      = .001). Additionally, the risk of CV events was significantly higher in the anti-LPL antibody-positive group, with a hazard ratio of 169.20 (95% confidence interval: 5.75\u20134981.54,\n                      <jats:italic>p<\/jats:italic>\n                      = .003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, the positivity rate of anti-LPL antibodies was high among Japanese patients with SLE. Additionally, a significantly higher incidence of CV events was observed in the anti-LPL antibody-positive group compared to that in the anti-LPL antibody-negative group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09612033251344051","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T09:33:01Z","timestamp":1747301581000},"page":"699-704","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of anti-lipoprotein lipase antibodies in Japanese patients with systemic lupus erythematosus"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0695-7981","authenticated-orcid":false,"given":"Taro","family":"Horino","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kashio","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Inotani","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202006020"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/184868"},{"key":"e_1_3_6_4_2","first-page":"917","article-title":"Comparable effects of traditional cardiovascular risk factors on subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis","volume":"38","author":"Quevedo-Abeledo JC","year":"2020","unstructured":"Quevedo-Abeledo JC, R\u00faa-Figueroa \u00cd, S\u00e1nchez-P\u00e9rez H, et al. Comparable effects of traditional cardiovascular risk factors on subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Rheumatol 2020; 38: 917\u2013924.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.10.002"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570161118666191227101636"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.01.009"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2017.09.001"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198905000-00002"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009122"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487314546826"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0003319720985337"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161121"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23018"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.30.1.7"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.02.029"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)66011-9"},{"key":"e_1_3_6_19_2","first-page":"1913","volume-title":"The metabolic basis of inherited disease","author":"Brunzell JD","year":"1995","unstructured":"Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, et al. (eds). The metabolic basis of inherited disease. New York: McGraw-Hill, 1995, pp. 1913\u20131932."},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10624"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20630"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310706"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600610"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221119329"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11264"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/174182679600300214"},{"key":"e_1_3_6_27_2","first-page":"791","article-title":"Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy","volume":"82","author":"Pruneta V","year":"1997","unstructured":"Pruneta V, Moulin P, Labrousse F, et al. Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy. J Clin Endocrinol Metab 1997; 82: 791\u2013796.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251344051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09612033251344051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09612033251344051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:28:55Z","timestamp":1777678135000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09612033251344051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/09612033251344051"],"URL":"https:\/\/doi.org\/10.1177\/09612033251344051","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}